264 related articles for article (PubMed ID: 25585249)
1. Mutation stability in primary and metastatic melanoma: what we know and what we don't.
Varada S; Mahalingam M
Histol Histopathol; 2015 Jul; 30(7):763-70. PubMed ID: 25585249
[TBL] [Abstract][Full Text] [Related]
2. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
3. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
4. [Translational research and diagnostics of melanoma].
Rüschoff J; Kleinschmidt M; Middel P
Pathologe; 2012 Nov; 33 Suppl 2():291-5. PubMed ID: 22968732
[TBL] [Abstract][Full Text] [Related]
5. Frequencies of KIT and GNAQ mutations in acral melanoma.
Puntervoll HE; Molven A; Akslen LA
J Cutan Pathol; 2014 Nov; 41(11):893-4. PubMed ID: 25363280
[No Abstract] [Full Text] [Related]
6.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.
Ponti G; Pellacani G; Tomasi A; Loschi P; Luppi G; Gelsomino F; Longo C
Dis Markers; 2014; 2014():671283. PubMed ID: 24591764
[TBL] [Abstract][Full Text] [Related]
8. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
Lee SH; Kim JE; Jang HS; Park KH; Oh BH; Shin SJ; Chung KY; Roh MR; Rha SY
Cancer Res Treat; 2018 Oct; 50(4):1378-1387. PubMed ID: 29361821
[TBL] [Abstract][Full Text] [Related]
9. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
10. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
[TBL] [Abstract][Full Text] [Related]
11. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.
Turajlic S; Furney SJ; Stamp G; Rana S; Ricken G; Oduko Y; Saturno G; Springer C; Hayes A; Gore M; Larkin J; Marais R
Ann Oncol; 2014 May; 25(5):959-67. PubMed ID: 24504448
[TBL] [Abstract][Full Text] [Related]
12. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
13. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
15. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
Lovly CM; Dahlman KB; Fohn LE; Su Z; Dias-Santagata D; Hicks DJ; Hucks D; Berry E; Terry C; Duke M; Su Y; Sobolik-Delmaire T; Richmond A; Kelley MC; Vnencak-Jones CL; Iafrate AJ; Sosman J; Pao W
PLoS One; 2012; 7(4):e35309. PubMed ID: 22536370
[TBL] [Abstract][Full Text] [Related]
16. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
18. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.
Henary H; Hong DS; Falchook GS; Tsimberidou A; George GC; Wen S; Wheler J; Fu S; Naing A; Piha-Paul S; Janku F; Kim KB; Hwu P; Kurzrock R
Ann Oncol; 2013 Aug; 24(8):2158-65. PubMed ID: 23576709
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]